Furthermore, DRP-104 maintained long-term suppression of the KEAP1 mutant PDX CTG743, as demonstrated by significant tumor regression followed by sustained maintenance of tumor growth inhibition during an extended dosing period of 50 days without evidence of resistance (fig. The gene discussed is KEAP1; the disease is neoplasm.